Terms: = Bone cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Treatment
182 results:
1. Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma.
Cheevapruk K; Ueno M; Sungwan P; Sittithumcharee G; Kariya R; Sampattavanich S; Okada S
Anticancer Res; 2024 Mar; 44(3):1023-1031. PubMed ID: 38423667
[TBL] [Abstract] [Full Text] [Related]
2. Regulation of the P53 tumor suppressor gene and the mcl-2 oncogene expression by an active herbal component delivered through a smart thermo-pH-sensitive PLGA carrier to improve Osteosarcoma treatment.
Akbari P; Taebpour M; Akhlaghi M; Hasan SH; Shahriyari S; Parsaeian M; Haghirosadat BF; Rahdar A; Pandey S
Med Oncol; 2024 Jan; 41(3):68. PubMed ID: 38289404
[TBL] [Abstract] [Full Text] [Related]
3. Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.
Zaremba-Pataj E; Patkowska E; Krzywdzińska A; Szumera-Ciećkiewicz A; Chlebowska-Tuz J
J Hematop; 2023 Mar; 16(1):39-47. PubMed ID: 38175371
[TBL] [Abstract] [Full Text] [Related]
4. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study.
Bock AM; Gile JJ; Larson MC; Poonsombudlert K; Tawfiq RK; Maliske S; Maurer MJ; Kabat BF; Paludo J; Inwards DJ; Ayyappan S; Link BK; Ansell SM; Habermann TM; Witzig TE; Nowakowski GS; Cerhan JR; Farooq U; Wang Y
Blood Cancer J; 2023 Nov; 13(1):169. PubMed ID: 37957158
[TBL] [Abstract] [Full Text] [Related]
5. [Clinical features and prognostic factors of elderly patients with mantle cell lymphoma].
Hao XY; Yang P; Zhang W; Liu H; Sun XH; Xiao XB; Wang JW; Li ZL; Li LH; Wang SY; He J; Li XL; Jing HM
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):495-500. PubMed ID: 37550206
[No Abstract] [Full Text] [Related]
6. Henoch-Schonlein Purpura, an Unusual Presentation of Acute Myeloid Leukemia.
Butt MA; Aamer S; Kapetanos A
Anticancer Res; 2023 Aug; 43(8):3579-3582. PubMed ID: 37500160
[TBL] [Abstract] [Full Text] [Related]
7. A secondary CD34+ acute lymphoblastic leukemia unmasked and mobilized by G-CSF in an autologous stem cell donor with testicular cancer.
Cooling L; Kelley J; Sexton E; Anand S; Hoffmann S
Transfusion; 2023 Apr; 63(4):684-689. PubMed ID: 36762622
[TBL] [Abstract] [Full Text] [Related]
8. Olive leaves extract alleviates inflammation and modifies the intrinsic apoptotic signal in the leukemic bone marrow.
Nath P; Modak S; Aktar T; Maiti S; Ghosh A; Singh R; Debnath M; Saha B; Maiti D
Front Immunol; 2022; 13():1054186. PubMed ID: 36741365
[TBL] [Abstract] [Full Text] [Related]
9. A novel mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
[TBL] [Abstract] [Full Text] [Related]
10. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S
Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560
[TBL] [Abstract] [Full Text] [Related]
11. Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
Pascual-Pasto G; Resa-Pares C; Castillo-Ecija H; Aschero R; Baulenas-Farres M; Vila-Ubach M; Burgueño V; Balaguer-Lluna L; Cuadrado-Vilanova M; Olaciregui NG; Martinez-Velasco N; Perez-Jaume S; de Alava E; Tirado OM; Lavarino C; Mora J; Carcaboso AM
Biochem Pharmacol; 2023 Feb; 208():115408. PubMed ID: 36603685
[TBL] [Abstract] [Full Text] [Related]
12. Targeting mcl-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Lasater EA; Amin DN; Bannerji R; Mali RS; Barrett K; Rys RN; Oeh J; Lin E; Sterne-Weiler T; Ingalla ER; Go M; Yu SF; Krem MM; Arthur C; Hahn U; Johnston A; Karur V; Khan N; Marlton P; Phillips T; Gritti G; Seymour JF; Tani M; Yuen S; Martin S; Chang MT; Rose CM; Pham VC; Polson AG; Chang Y; Wever C; Johnson NA; Jiang Y; Hirata J; Sampath D; Musick L; Flowers CR; Wertz IE
Am J Hematol; 2023 Mar; 98(3):449-463. PubMed ID: 36594167
[TBL] [Abstract] [Full Text] [Related]
13. Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
Kotchetkov R; Drennan IR; Susman D; DiMaria E; Gerard L; Nay D; Prica A
Int J Cancer; 2023 May; 152(9):1884-1893. PubMed ID: 36545885
[TBL] [Abstract] [Full Text] [Related]
14. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Epperla N; Switchenko J; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M; Karmali R; Sawalha Y; Hill BT; Ghosh N; Park SI; Bond DA; Hamadani M; Fenske TS; Martin P; Malecek MK; Kahl BS; Flowers CR; Link BK; Kaplan LD; Inwards DJ; Feldman AL; Hsi ED; Maddocks K; Blum KA; Bartlett NL; Cerhan JR; Leonard JP; Habermann TM; Maurer MJ; Cohen JB
Blood Adv; 2023 Jun; 7(11):2287-2296. PubMed ID: 36516079
[TBL] [Abstract] [Full Text] [Related]
15. BRUIN mcl-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
[TBL] [Abstract] [Full Text] [Related]
16. bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.
Aksoy O; Lind J; Sunder-Plaßmann V; Vallet S; Podar K
Cytokine; 2023 Jan; 161():156062. PubMed ID: 36332463
[TBL] [Abstract] [Full Text] [Related]
17. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
Kennedy VE; Perkins C; Reiter A; Jawhar M; Lübke J; Kluin-Nelemans HC; Shomali W; Langford C; Abuel J; Hermine O; Niedoszytko M; Gorska A; Mital A; Bonadonna P; Zanotti R; Tanasi I; Mattsson M; Hagglund H; Triggiani M; Yavuz AS; Panse J; Christen D; Heizmann M; Shoumariyeh K; Müller S; Elena C; Malcovati L; Fiorelli N; Wortmann F; Vucinic V; Brockow K; Fokoloros C; Papageorgiou SG; Breynaert C; Bullens D; Doubek M; Ilerhaus A; Angelova-Fischer I; Solomianyi O; Várkonyi J; Sabato V; Rüfer A; Schug TD; Hermans MAW; Fortina AB; Caroppo F; Bumbea H; Gulen T; Hartmann K; Elberink HO; Schwaab J; Arock M; Valent P; Sperr WR; Gotlib J
Blood Adv; 2023 May; 7(9):1713-1724. PubMed ID: 36094848
[TBL] [Abstract] [Full Text] [Related]
18. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
[TBL] [Abstract] [Full Text] [Related]
19. Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer.
Petrone G; Gaulin C; Derkach A; Kishtagari A; Robson ME; Parameswaran R; Stein EM
Haematologica; 2023 Jan; 108(1):161-170. PubMed ID: 35770528
[TBL] [Abstract] [Full Text] [Related]
20. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
Ung J; Tan SF; Fox TE; Shaw JJP; Vass LR; Costa-Pinheiro P; Garrett-Bakelman FE; Keng MK; Sharma A; Claxton DF; Levine RL; Tallman MS; Cabot MC; Kester M; Feith DJ; Loughran TP
Blood Rev; 2022 Sep; 55():100950. PubMed ID: 35487785
[TBL] [Abstract] [Full Text] [Related]
[Next]
